March 21, 2003
Immunotherapy Weekly
CTLA4 gene is found associated with susceptibility to MS.
A study from the United States "comprehensively screened CTLA4 for novel genetic variations in patients with MS. We studied genetic variations by association methods in a population based sample of 122 sporadic patients with MS and 244 age, gender and ethnicity matched controls, and by linkage and family based association methods in 395 individuals from 59 American multiplex pedigrees with 141 affected individuals.
"Being homozygous for AT(8)(common) allele of the 3'(514) microsatellite (OR=1.69; CI=0.99-2.86) and for the common 5'(318)*C/E1(49)*A/ 3'(514*AT(8) haplotype (OR=1.96; CI=1.13-3.39) was associated with increased susceptibility to MS in Olmsted County. The genotype frequencies of other individual polymorphisms were not significantly different between cases and controls. A pooled analysis of association studies revealed an OR of 1.28 (95% CI=1.01-1.63; p=0.043) for 5'(-318)*C homozygotes and 1.28 (95% CI=1.08-1.51; p=0.005) for the 3'(514)*AT(8) allele. We did not detect linkage with MS susceptibility in multiplex families. We did not find a strong association with age at onset, disease course or severity. CTLA-4 is associated with susceptibility to MS," stated O.H. Kantarci and coauthors.
Kantarci and colleagues published the results of their study in Journal of Neuroimmunology (CTLA4 is associated with susceptibility to multiple sclerosis. J Neuroimmunol, 2003;134(1-2):133-141).
The corresponding author for this report is B.G. Weinshenker, Mayo Clinic & Mayo Foundation, Department of Neurology, 200 1st St. SW, Rochester, MN 55905, USA.
To subscribe to the Journal of Neuroimmunology, contact the publisher: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands.
The information in this article comes under the major subject areas of Epidemiology, Neurology, Genetics and Genomics, Immunology, Multiple Sclerosis, Inherited MS Susceptibility, CTLA4 Gene, Genetic Susceptibility and Risk Factor.
This article was prepared by Immunotherapy Weekly editors from staff
and other reports.
© Copyright 2003 Immunotherapy Weekly